Display options
Cite
Jacobson LP, Phair JP, Yamashita TE. Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep. 2002;4(1):88-96doi: 10.1007/s11908-002-0072-5.
Jacobson, L. P., Phair, J. P., & Yamashita, T. E. (2002). Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Current infectious disease reports, 4(1), 88-96. https://doi.org/10.1007/s11908-002-0072-5
Jacobson, Lisa P., et al. "Virologic and Immunologic Response to Highly Active Antiretroviral Therapy." Current infectious disease reports vol. 4,1 (2002): 88-96. doi: https://doi.org/10.1007/s11908-002-0072-5
Jacobson LP, Phair JP, Yamashita TE. Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep. 2002 Feb;4(1):88-96. doi: 10.1007/s11908-002-0072-5. PMID: 11853662.
Copy Download .nbib Format: NLM
Share it on

Curr Infect Dis Rep. 2002 Feb;4(1):88-96. doi: 10.1007/s11908-002-0072-5.

Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Current infectious disease reports

Lisa P. Jacobson, John P. Phair, Traci E. Yamashita

Affiliations

  1. Room E7006, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA. [email protected]

PMID: 11853662 DOI: 10.1007/s11908-002-0072-5

Abstract

Highly active antiretroviral therapy (HAART) delays clinical progression to AIDS by suppressing viral replication, allowing the immune system to reconstitute. These virologic and immunologic consequences do not occur uniformly among HAART users; markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while under HAART. In this paper, we review studies describing the heterogeneous virologic and immunologic progression following the initiation of HAART, and update findings obtained in the Multicenter AIDS Cohort Study that show that CD4 cell count and history of antiretroviral therapy at the time of initiation are independent determinants of response.

References

  1. J Infect Dis. 1999 Apr;179(4):790-8 - PubMed
  2. Nature. 1998 Dec 17;396(6712):690-5 - PubMed
  3. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9 - PubMed
  4. AIDS. 2000 May 5;14(7):821-6 - PubMed
  5. J Infect Dis. 1999 Aug;180(2):530-3 - PubMed
  6. AIDS. 2001 Apr 13;15(6):735-46 - PubMed
  7. Lancet. 1997 May 3;349(9061):1294 - PubMed
  8. JAMA. 2001 Nov 28;286(20):2560-7 - PubMed
  9. Clin Infect Dis. 2001 Apr 15;32(8):1231-2 - PubMed
  10. J Infect Dis. 2001 Dec 1;184(11):1402-11 - PubMed
  11. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):372-6 - PubMed
  12. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):82-92 - PubMed
  13. JAMA. 1998 Feb 11;279(6):450-4 - PubMed
  14. Ann Intern Med. 1996 Jun 15;124(12):1039-50 - PubMed
  15. Clin Infect Dis. 1999 Dec;29(6):1423-30 - PubMed
  16. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):168-75 - PubMed
  17. AIDS. 2000 Jul 28;14(11):1545-52 - PubMed
  18. N Engl J Med. 1997 Sep 11;337(11):725-33 - PubMed
  19. Am J Epidemiol. 1995 Aug 1;142(3):323-30 - PubMed
  20. AIDS. 2000 Dec 1;14(17):2788-90 - PubMed
  21. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):313-9 - PubMed
  22. AIDS. 1999 Feb 4;13(2):203-12 - PubMed
  23. Lancet. 2000 Nov 25;356(9244):1800-5 - PubMed
  24. J Infect Dis. 2000 Mar;181(3):946-53 - PubMed
  25. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):161-7 - PubMed
  26. JAMA. 1999 Aug 25;282(8):734 - PubMed
  27. Cytometry. 1993;14(3):307-17 - PubMed
  28. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):350-64 - PubMed
  29. AIDS. 2001 Nov 9;15(16):2109-17 - PubMed
  30. N Engl J Med. 1998 Mar 26;338(13):853-60 - PubMed
  31. AIDS. 1999 Apr 16;13(6):F35-43 - PubMed
  32. HIV Clin Trials. 2000 Jul-Aug;1(1):60-110 - PubMed
  33. Clin Infect Dis. 1999 Jul;29(1):75-81; discussion 82-4 - PubMed
  34. AIDS. 1998 Nov 12;12(16):2193-202 - PubMed
  35. J Clin Epidemiol. 2001 Feb;54(2):149-56 - PubMed
  36. AIDS. 2000 Sep 8;14(13):1955-60 - PubMed
  37. Ann Intern Med. 2000 Sep 19;133(6):401-10 - PubMed
  38. Am J Epidemiol. 1987 Aug;126(2):310-8 - PubMed
  39. Clin Infect Dis. 2001 Aug 15;33(4):466-72 - PubMed
  40. HIV Clin Trials. 2001 Jan-Feb;2(1):6-16 - PubMed
  41. AIDS. 1998 Jul 30;12(11):F131-5 - PubMed
  42. AIDS. 1999 Jul 9;13(10):1187-93 - PubMed
  43. AIDS. 2001 Sep 28;15(14):1749-56 - PubMed
  44. J Infect Dis. 2000 Nov;182(5):1527-30 - PubMed
  45. JAMA. 2000 Jan 19;283(3):381-90 - PubMed
  46. Am J Epidemiol. 2002 Apr 15;155(8):760-70 - PubMed
  47. Lancet. 1999 Mar 13;353(9156):863-8 - PubMed
  48. Am J Epidemiol. 2000 Nov 15;152(10):923-33 - PubMed
  49. AIDS. 2000 Sep 8;14(13):1887-97 - PubMed
  50. J Infect Dis. 2001 May 1;183(9):1328-35 - PubMed
  51. Arch Intern Med. 2000 Apr 24;160(8):1123-32 - PubMed
  52. J Clin Invest. 1999 Feb;103(4):453-60 - PubMed
  53. J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):296-305 - PubMed
  54. Blood. 2000 Jul 1;96(1):250-8 - PubMed
  55. J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 - PubMed
  56. Clin Immunol Immunopathol. 1990 May;55(2):173-86 - PubMed
  57. Arch Intern Med. 2000 Apr 24;160(8):1134-40 - PubMed
  58. J Infect Dis. 2001 Apr 15;183(8):1290-4 - PubMed
  59. JAMA. 1998 Nov 4;280(17):1497-503 - PubMed
  60. AIDS. 2001 Nov 23;15(17):2259-66 - PubMed
  61. AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):277-86 - PubMed
  62. BMJ. 1997 Nov 8;315(7117):1194-9 - PubMed

Publication Types